Doripenem is allotment of Johnson &’ Johnson’s anti-infective R&D portfolio afterward the accretion of Peninsula Pharmaceuticals in 2005. The drug, a affiliate of the carbapenem chic of Β-lactam antibiotics, is adumbrated for the analysis of austere bacterial infections in hospitalised patients.
Marketed beneath the cast name Doribax in Europe and the US, it is an accustomed analysis for complicated intra-abdominal (cIAI) and complicated urinary amplitude infections (cUTI), including pyelonephritis in adults.
In Europe it is aswell accountant for analysis of nosocomial pneumonia (NP), including ventilator-associated pneumonia (VAP); final approval for these break was acquired in 2008. In the US, however, the FDA has requested added advice afore it will sanction approval of Doribax for these added indications.